IDDI actively participates in research in the fields of biostatistics and clinical epidemiology and collaborates with major academic institutions, research groups and clinical groups, including:
FRANCE
- Association Européenne de Recherche en Oncologie (AERO) Créteil, France: Phase II and phase IV trials in early rectal, early and advanced breast cancer
- Fédération Francophone de Cancérologie Digestive FFCD: PETACC 8 trial, analyses to explore Cetuximab as adjuvant to therapy of colorectal cancer.
- Meta-Analysis Group In Cancer (MAGIC), Créteil, France: Meta-analyses in colorectal, breast, ovarian and oesophageal cancer, and melanoma
- ARCAD, GERCOR, IGR, iPRI (International Prevention Research Institute)
BENELUX
- Breast International Group (BIG), Brussels, Belgium: Phase III trial in early breast cancer
- European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium: Meta-analysis of advanced breast cancer trials
- Institut Jules Bordet, Brussels, Belgium: Meta-analysis of trials in advanced breast cancer
- TRANSBIG, Brussels, Belgium: collaborative project for a clinical trial using molecular profiling of patients with early breast cancer, a project funded by the European Unio
- Hasselt University ,Diepenbeek, Belgium: Validation of surrogate endpoints in clinical trials, analysis of longitudinal data, statistical methods for meta-analysis
- KUL, UCL, ULB (SMART)
USA AND CANADA
- Translational Research In Oncology (TRIO) Edmonton (Canada) and Paris, France: Phase III trials in early and advanced cancer
- Cleveland Clinic Coordinating Center for Clinical Research (C5 Research), Cleveland, USA: IDMC Statistical support for cardiovascular trials
- National Surgical Adjuvant Breast and Bowel Project (NSABP) Pittsburgh, USA: Phase II trials in oncology
UNITED KINGDOM
- Medical Research Council (MRC)
ITALY
- European Institute of Oncology, Milan : Validation of genomic signature
ASIA
- Nagoya University
- Indian Oncology Co-Operative Network - ICON - India
- Tata Memorial - India
AUSTRALIA